Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 161Squamous Cell Carcinoma of Head and Neck 95Head and Neck Neoplasms 95Colonic Neoplasms 46Rectal Neoplasms 39Neoplasm Metastasis 35Carcinoma, Non-Small-Cell Lung 29Carcinoma, Squamous Cell 25Pancreatic Neoplasms 18Neoplasms 18Esophageal Neoplasms 18Lung Neoplasms 17Stomach Neoplasms 13Laryngeal Neoplasms 12Recurrence 11Oropharyngeal Neoplasms 11Mouth Neoplasms 11Esophageal Squamous Cell Carcinoma 11Colorectal Cancer Metastatic 10Tongue Neoplasms 9Carcinoma 9Breast Neoplasms 9Nasopharyngeal Carcinoma 8Hypopharyngeal Neoplasms 8Adenocarcinoma Of Esophagus 8Laryngeal Diseases 6Salivary Gland Neoplasms 5Neoplasms, Squamous Cell 5Glioblastoma 5Uterine Cervical Neoplasms 4

Interventions

Cyclophosphamide 21Cytarabine 15blinatumomab 13fludarabine 12Azacitidine 10venetoclax 9fludarabine phosphate 9Blood Specimen Collection 8Methotrexate 7Lenalidomide 7Dexamethasone 7Rituximab 6Mercaptopurine 6Daunorubicin 6Vincristine 5daratumumab 4Whole-Body Irradiation 4Melphalan 4Etoposide 4Busulfan 4obinutuzumab 3Radiotherapy 3Neoadjuvant Therapy 3Maintenance 3Liquid Biopsy 3Immunotherapy, Adoptive 3Idarubicin 3Granulocyte Colony-Stimulating Factor 3Drug Therapy 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasm, Residual × Cetuximab × Clear all
NCT06358430 2026-05-20

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

M.D. Anderson Cancer Center

Phase 1 Recruiting
42 enrolled
Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡